% | $
Quotes you view appear here for quick access.

Alkermes plc Message Board

  • randywise_2000 randywise_2000 Oct 12, 2010 7:38 PM Flag

    pathetic sales prediction for Vivitrol

    Leerink Swann Research Analyst Steve Yoo has said Vivitrol's sales could reach $125 million by 2015 with wider approval.

    Cambridge, Massachusetts-based Alkermes reported net sales of $20.2 million for fiscal 2010, compared with $16.9 million in 2009 for Alkermes and its then-partner Cephalon Inc (CEPH.O).

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • This is not a very important drug at all. They will be lucky to make a profit on it. The key for ALKS is not only Bydureon but other drugs of that nature which they can assist in making patients take less frequenetly and just reaping a % of sales with no risk. That is a great deal, and that is the real potential here. I am not sure why they got ditched by J&J I think it was on that other one they were doing the same thing for, but evidently they are not the only guys on the block with this kind of product. Next up I think they may be working with Amylin for a monthly instead of weekly version of Bydureon so that will be the next time to revisit this stock I think after Bydureon gets approved.

56.30+12.79(+29.40%)3:16 PMEDT